Tislelizumab Combined With Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the
safety, tolerability, efficacy in combination with tislelizumab and mitoxantrone
hydrochloride liposome combination treatment in patients with relapsed or refractory
Extranodal Natural Killer/T Cell Lymphoma（NKTCL）